FDA has accepted a supplemental New Drug Application for Rubraca (rucaparib) and granted priority review status to the application with a Prescription Drug User Fee Act date of May 15.
In his new book, “No More Tears: The Dark Secrets of Johnson & Johnson,” Gardiner Harris, who was previously the public health and pharmaceutical business reporter for The New York Times, talks about the history of the overuse of red blood cell growth factors in oncology.
